Alembic Pharmaceuticals gains 2% on USFDA approval for Dapagliflozin tablets

The company now have a total of 99 ANDA approvals (88 final approvals and 11 tentative approvals) from USFDA.

Shares of Alembic Pharmaceuticals gained 2 percent intraday July 23 after the company received approval from the US Food & Drug Administration (USFDA).


The company has received tentative approval from the USFDA for its abbreviated new drug application (ANDA) Dapagliflozin tablets, 5 mg, and 10 mg, as per company release on BSE.

Dapagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The company now have a total of 99 ANDA approvals (88 final approvals and 11 tentative approvals) from USFDA.

At 10:48 hrs Alembic Pharmaceuticals was quoting at Rs 523, up to Rs 10.90, or 2.13 percent on the BSE.

Get a 2 days free trial in Stock Market Tips and MCX Tips  

Comments

Post a Comment

Popular posts from this blog

Rupee opens lower at 68.90 per dollar

Image
On July 30 the Indian rupee ended 10 paise lower at 68.86 against the US dollar. The Indian rupee opened marginally lower at 68.90 per dollar on Wednesday against previous close 68.86. On July 30 the Indian rupee ended 10 paise lower at 68.86 against the US dollar on the back of rising crude oil prices and heavy selling in domestic equities. The dollar-rupee August contract on the NSE was at 69.05 in the previous session. Open interest increased 23.46% in the previous session, reported ICICIdirect. We expect the USD-INR to find supports at lower levels. Utilize downsides in the pair to initiate long positions, it added. Get a 2 days free trial in Stock Market Tips and MCX Tips 
Read more

Rupee opens higher at 69.72 per dollar

Image
Today, USD-INR pair is expected to quote in the range of 69.60 and 70.20, says Motilal Oswal. The Indian rupee opened higher by 11 paise at 69.72 per dollar on Thursday versus previous close 69.83. The local currency fell for the second straight day on May 29 as it lost 14 paise to end the session at 69.83 against the US dollar. The rupee was weighed down in yesterday’s session following broad strength in the dollar against its major crosses. Volatility for the currency could remain low ahead of important economic numbers that will be released tomorrow, said Motilal Oswal. GDP and fiscal number that will be released on the domestic front could set the tone for RBI meeting that is scheduled next week. The expectation is that the central bank could cut rates and a dovish stance could keep the rupee weighed down. Broadly, trade war concern is keeping most market participants on the edge. Today, USD-INR pair is expected to quote in the range of 69.60 and 70.20, it...
Read more

Rakesh Jhunjhunwala's Rare Enterprises buys 1% stake in Jubilant Life

Image
Rakesh Radheshyam Jhunjhunwala already held 1.90 percent stake in Jubilant as per the shareholding pattern of June 2019. Rare Enterprises, owned by the ace investor and billionaire Rakesh Jhunjhunwala, picked up 1 percent stake in Jubilant Life Sciences as per bulk deals data available on National Stock Exchange on July 30. The private equity company acquired 2,013,626 shares of the pharma firm at Rs 436.23 per share and sold 263,626 shares at Rs 435.75 per share. Therefore, the net acquisition of Rare Enterprises is 17.5 lakh shares representing 1.098 percent of total paid-up equity. Rakesh Radheshyam Jhunjhunwala already held 1.90 percent stake in Jubilant, as per the shareholding pattern of June 2019. East Bridge Capital Master Fund also increased its stake in the company by acquiring 1,250,000 shares at Rs 435 per share. The above acquisition of shares is on top of 4.63 percent stake already held by East Bridge Capital in the company as of June 2019. T...
Read more